Cambridge Cancer Genomics
Cambridge Cancer Genomics ensures that each patient has the right treatment, at the right time, to beat their cancer. They are building a precision Artificial Intelligence platform for personalised cancer care.
What impact is Cambridge Cancer Genomics making?
Our technology can detect relapse earlier than the standard of care, predict response to therapy more accurately and reduce ineffective treatment regimens. The reality is that first line therapy still fails for 2 out of 3 cancer patients and it can take up to 6 months to realise when a drug isn’t working. With CCG’s platform, all patients will have access to the best cancer care.
How has Cambridge Cancer Genomics grown?
CCG started in 2018 with a team of 5, occupying a 500sqft office. We are now 25 people and 4500sqft. We sponsor PhD students in Edinburgh and KCL and have clinical facilities in California with our research and development headquarters in Cambridge.
How has the programme helped you?
Our business advisor has helped CCG cope with this rapid expansion by guiding the board and management team in setting up proper governance and processes as befitting a multinational start-up.
“Programmes like this are helping to transform Cambridge into the world class start-up hub it should be.”
Find out more about Cambridge Cancer Genomics